OK-432

Known as: Streptococcal OK 432, Streptococcal OK432, 432 ok 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
OBJECTIVES To determine the efficacy and safety of the immunostimulant OK-432 (Picibanil) as a treatment option in the management… (More)
Is this relevant?
2004
2004
OBJECTIVE To describe our experience with sclerosing treatment of lymphangiomas in the head and neck region by intralesional… (More)
Is this relevant?
2002
2002
Purpose: To determine the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas. Methods: The treatment was begun… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
2000
2000
Over a period of seven years, 15 patients (aged from birth to 15 years; median 22 months) with lymphangioma were treated with OK… (More)
  • table 1
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Intralesional injection of OK-432 (lyophilized incubation mixture of group A Streptococcus pyogenes of human origin) is safe and… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
OBJECTIVE To assess the efficacy of OK-432 sclerotherapy in the treatment of lymphangiomas. DESIGN Nonrandomized trial; follow… (More)
Is this relevant?
1995
1995
The authors present two cases of lymphangioma of the cervicofacial region, treated with a new investigational drug in North… (More)
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Intralesional injection of OK-432 was employed to treat 64 lymphangiomas between 1986 and 1992. This was used as primary therapy… (More)
Is this relevant?
1991
1991
To avoid surgery-related complications, intralesional OK-432 therapy was used in 23 patients with unresectable lymphangiomas… (More)
Is this relevant?
Highly Cited
1987
Highly Cited
1987
Nine patients with cystic hygroma were treated with a new sclerosing therapy consisting of intracystic injection of OK-432 (group… (More)
Is this relevant?